

### EXAMINER'S AMENDMENT

#### *Continued Examination Under 37 CFR 1.114*

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 20 April 2007 and the supplemental amendment filed on 19 November 2007 have been entered.

2. The requirement for restriction between diseases and conditions of the central nervous system and peripheral nervous system which are characterized by a lesion is hereby **VACATED**. The requirement for restriction between groups I and II, along with the restriction between other diseases and conditions not characterized by a lesion, as set forth in the restriction requirement is maintained.

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in telephone interviews with Roger Browdy on 25 February 2008 and 26 February 2008.

4. The claims are amended as follows:

Claim 1 has been re-written as follows:

--A method for down-regulating the suppressive activity of CD4<sup>+</sup>CD25<sup>+</sup> T<sub>reg</sub> cells at the site of a lesion in the central or peripheral nervous system, comprising administering to a subject in need, an amount of poly-Glu,Tyr effective to down-regulate the suppressive activity of CD4<sup>+</sup>CD25<sup>+</sup> T<sub>reg</sub> cells at the lesion site.---

Claims 5 – 8, 10 – 11, and 13 have been rejoined and allowed. Claims 12 and 14 – 18 have been canceled.

Art Unit: 1649

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL KOLKER whose telephone number is (571)272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/D.K./

Patent Examiner, Art Unit 1649

March 10, 2008

/Robert C. Hayes, Ph.D./

Primary Examiner, Art Unit 1649